Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
For women receiving breast RT who develop a severe skin reaction during treatment, what is your threshold for giving a treatment break?
When do you institute a treatment break for skin reaction for patients who receive breast radiation?
Answer from: Radiation Oncologist at Community Practice
I would for symptomatic grade 3 Reaction although in era of hypofractination it is very uncommon. Sometimes would do boost RT in the break period
Sign in or Register to read more
3019
Related Questions
How do your PMRT recommendations change with ITCs after neoadjuvant chemotherapy if they had SLNB only versus ALND in light of B51?
Do you start systemic therapy for patients with previously localized HR+ breast cancer developing solitary bone metastasis which is now triple negative if there are no other sites of disease after metastasis-directed radiation?
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
Is Stage I B/L Breast, ER+ Cancer a contraindication to breast radiation omission after breast conservation surgery?
Would you offer APBI to a patient with very large breast anatomy and a small lumpectomy cavity after an oncoplastic closure?
In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?
What are your top takeaways in Medical Oncology from SABCS 2024?
What is your preferred sequencing of adjuvant chemotherapy and PMRT for node + breast cancer?
Is DCISionRT appropriate for multifocal DCIS?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?